This application of the Comprehensive Cancer Center of Wake Forest University (CCCWFU) requests renewal of its Cancer Center Support Grant for Years 33 through 37. During the current grant period, peer-reviewed annual direct cancer funding increased from $10.8 to $25.4 million, NCI funding increased from $5.1 to $12 million, and annual direct funding per member increased from $106,000 to $233,000. Interprogrammatic publications increased from 9.1% to 11.8%, intraprogrammatic publications increased from 16.7% to 28.6%, and interdepartmental publications increased from 17.4% to 28.7%. Formal collaboration (co-investigators, consultants, or collaborators) with other Cancer Center members is present on 68.5% of peer-reviewed research grants listed in summary II. In the current grant cycle we have made few structural changes, and instead focused on the execution of our scientific vision. Support is requested for four Programs: Cell Growth and Survival, DNA Damage and Cellular Defense, Clinical Research and Cancer Control as well as seven shared resources: Biomolecular Resource Laboratory, Cell Culture and Viral Vector, Microarray, Cellular Imaging, Tumor Tissue, Biostatistics, and Clinical Research Management. During this funding period, the CCCWFU opened a new 225,000 sq.ft. outpatient cancer center, and continued its longstanding focus and unique contributions to the cancer problems in our 7 state catchment area. The blueprint for our next five years is embodied in this application, which provides the Center's vision of how it can reduce the burden of cancer in our region and in the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA012197-34S4
Application #
7932455
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
2009-09-30
Project End
2012-09-29
Budget Start
2009-09-30
Budget End
2012-09-29
Support Year
34
Fiscal Year
2009
Total Cost
$1,434,256
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Faig, Jennifer; Haughton, Michael; Taylor, Richard C et al. (2018) Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy. Am J Clin Oncol 41:432-440
Melvin, Ryan L; Xiao, Jiajie; Godwin, Ryan C et al. (2018) Visualizing correlated motion with HDBSCAN clustering. Protein Sci 27:62-75
Swanner, Jessica; Singh, Ravi (2018) Synthesis, Purification, Characterization, and Imaging of Cy3-Functionalized Fluorescent Silver Nanoparticles in 2D and 3D Tumor Models. Methods Mol Biol 1790:209-218
Nelson, Kimberly J; Perkins, Arden; Van Swearingen, Amanda E D et al. (2018) Experimentally Dissecting the Origins of Peroxiredoxin Catalysis. Antioxid Redox Signal 28:521-536
Feliz-Mosquea, Yismeilin R; Christensen, Ashley A; Wilson, Adam S et al. (2018) Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Res Treat 172:69-82
Holmila, Reetta J; Vance, Stephen A; Chen, Xiaofei et al. (2018) Mitochondria-targeted Probes for Imaging Protein Sulfenylation. Sci Rep 8:6635
Rego, Stephen L; Harvey, Scott; Simpson, Sean R et al. (2018) TREX1 D18N mice fail to process erythroblast DNA resulting in inflammation and dysfunctional erythropoiesis. Autoimmunity :1-12
Li, X C; Wang, M Y; Yang, M et al. (2018) A mutational signature associated with alcohol consumption and prognostically significantly mutated driver genes in esophageal squamous cell carcinoma. Ann Oncol 29:938-944
Godwin, Ryan C; Macnamara, Lindsay M; Alexander, Rebecca W et al. (2018) Structure and Dynamics of tRNAMet Containing Core Substitutions. ACS Omega 3:10668-10678
Lu, Yong; Wang, Qiang; Xue, Gang et al. (2018) Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell 33:1048-1060.e7

Showing the most recent 10 out of 548 publications